Even in this population, the 15 mg dose produced average weight loss of 13.4% outperforming semaglutide in comparable diabetic populations
This is a mechanism most health articles do not discuss
Im excited and proud of our cutting-edge formulation that uses both clinically-studied and patented ingredients to increase GLP-1 levels in the body, naturally. Glucagon-like peptide-1 (GLP-1) agonists are a part of a class of medications used to treat type 2 diabetes mellitus (T2DM) and obesity, according to the National Library of Medicine
[1] [3] Other significant warnings include risks of pancreatitis, gallbladder disease, acute kidney injury with dehydration, diabetic retinopathy complications, and hypoglycemia when combined with insulin or sulfonylureas
The dual mechanism provides multiple pathways for weight reduction
2016: The FDA New Drug Application is filed